Radicle Science tests nutrition products in trials

Most wellness products reach U.S. shelves without full-formulation clinical trials, a gap Radicle Science says its “evidence-first” approach aims to close, positioning the model as a new standard for precision nutrition development.
Large-scale, multi-arm trial launches
Radicle Science partnered with biotech firm Holobiome to run a 20-arm, decentralized study that will test 19 prebiotic blends against a placebo in more than 6,000 participants. The trial combines microbiome sequencing, blood panels, wearable data, AI analytics, food diaries and questionnaires to generate a full data set.
“You get to test all these different things, figure out which ones have efficacy, and which ones have the right consumer impressions,” said Jeff Chen, MD, MBA, co-founder and CEO of Radicle Science. He added that the design allows simultaneous claim substantiation through proper blinding, placebo control, multiplicity correction and statistical power.
Beyond efficacy, Chen says the platform can feed patent strategies. Data mined from the trial can support composition and method-of-use patents, potentially fitting within the one-year window after filing a provisional patent. “The reason people don’t use trial data to back up patents is, when are you completing a trial within one year of filing a provisional prior to launching the trial? Trials don’t get turned around that fast,” he explained.
The study’s three stated goals are: first, to identify ready-to-deploy food-based solutions for mental wellness; second, to map the gut microbiome’s links to proteomic and functional health outcomes; and third, to prove that citizen-science trials can meet pharma-grade rigor while vastly improving efficiency.
First results are slated for the second half of 2027, giving companies a timeline to align product pipelines with emerging evidence.
Commercial pathways and licensing models
While Radicle Science will not sell products derived from the trial, it outlines several routes for brands. Holobiome owns the tested prebiotic formulas and can license them to manufacturers. A brand could market a powder identical to the study version, allowing consumers to mix it into drinks or foods.
Chen cautions that a stand-alone powder may not achieve the same population reach as an ingredient embedded in everyday foods. He notes that processing—such as heating—can alter a compound’s activity, potentially affecting trial outcomes when the formula is incorporated into a complex matrix.
Another model involves selling the clinically proven ingredient to food or supplement makers, who would then adapt it to their product formats. A third option envisions licensing multiple formulas together with a matching algorithm that recommends the best blend for an individual’s microbiome profile and mental-wellness goals. For example, he suggests that such brands could also offer specific tests for consumers to determine which formula is the best fit for their microbiome or mental wellness needs. Although some companies already offer such services, Chen says the Radicle Science trial would offer better data to base decisions on. “We have randomized controlled data showing which subpopulations responded to which of these formulations.”
Proof of concept and broader applications
Evidence-first trials aim to demonstrate that large-scale citizen-science studies can meet pharmaceutical-grade rigor while delivering faster results. The methodology relies on randomization, placebo control, blinding and statistical correction to generate causal findings rather than simple correlations.
By integrating microbiome sequencing, proteomic analysis, wearable metrics and detailed food logs, the multi-omics approach creates a richer data set than traditional studies.
